629 related articles for article (PubMed ID: 22828645)
21. Reactogenicity and immunogenicity of combined Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine booster dose coadministered with measles, mumps, and rubella vaccine.
Carmona A; Miranda M; Barrio F; De Vicente A; Mares J; Muñoz E; Diez-Delgado J; Alonso A; Giménez-Sánchez F; Merino J; García-Corbeira P; Maechler G; Boutriau D;
Pediatr Infect Dis J; 2010 Mar; 29(3):269-71. PubMed ID: 19952860
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ
BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae Type b and Neisseria meningitidis Serogroup C-tetanus toxoid conjugate vaccine coadministered with a Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months.
Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-Del-Rí M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Collard A; Boutriau D; Schuerman L; Jacquet JM;
Pediatr Infect Dis J; 2007 Jan; 26(1):1-7. PubMed ID: 17195697
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
[TBL] [Abstract][Full Text] [Related]
27. Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of age.
Marshall GS; Blatter M; Marchant C; Aris E; Mesaros N; Miller JM
Pediatr Infect Dis J; 2013 Jun; 32(6):662-8. PubMed ID: 23340564
[TBL] [Abstract][Full Text] [Related]
28. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
Szenborn L; Czajka H; Brzostek J; Konior R; Caubet M; Ulianov L; Leyssen M
Pediatr Infect Dis J; 2013 Jul; 32(7):777-85. PubMed ID: 23838777
[TBL] [Abstract][Full Text] [Related]
29. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers.
Bryant KA; Marshall GS
Expert Rev Vaccines; 2011 Jul; 10(7):941-50. PubMed ID: 21806393
[TBL] [Abstract][Full Text] [Related]
30. The immunogenicity and safety of a Hib-MenAC vaccine: a non-inferiority randomized, observer-blind trial in infants aged 3-5 months.
Wang YX; Tao H; Hu JL; Li JX; Dai WM; Sun JF; Liu P; Tang J; Liu WY; Zhu FC
Expert Rev Vaccines; 2017 May; 16(5):515-524. PubMed ID: 28277801
[TBL] [Abstract][Full Text] [Related]
31. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
[TBL] [Abstract][Full Text] [Related]
34. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
35. B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody.
Perrett KP; Jin C; Clutterbuck E; John TM; Winter AP; Kibwana E; Yu LM; Curtis N; Pollard AJ
J Immunol; 2012 Sep; 189(5):2673-81. PubMed ID: 22855707
[TBL] [Abstract][Full Text] [Related]
36. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.
Marshall GS; Marchant CD; Blatter M; Friedland LR; Aris E; Miller JM
Hum Vaccin; 2011 Feb; 7(2):258-64. PubMed ID: 21307655
[TBL] [Abstract][Full Text] [Related]
37. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
Klein NP; Abu-Elyazeed R; Cornish M; Leonardi ML; Weiner LB; Silas PE; Grogg SE; Varman M; Frenck RW; Cheuvart B; Baine Y; Miller JM; Leyssen M; Mesaros N; Roy-Ghanta S
Vaccine; 2017 Jun; 35(28):3564-3574. PubMed ID: 28536030
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants.
Khatami A; Snape MD; Ohene-Kena B; Young K; Oeser C; Michaelis LJ; Macleod E; Smee H; Van Der Meeren O; Leyssen M; Caubet M; Yu LM; Heath PT; Faust SN; Finn A; Pollard AJ
Pediatr Infect Dis J; 2013 Jun; 32(6):675-81. PubMed ID: 23348809
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants.
Klein NP; Abu-Elyazeed R; Baine Y; Cheuvart B; Silerova M; Mesaros N
Hum Vaccin Immunother; 2019; 15(2):327-338. PubMed ID: 30252603
[TBL] [Abstract][Full Text] [Related]
40. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
